Matthias W Beckmann
Overview
Explore the profile of Matthias W Beckmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
764
Citations
21402
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lehle S, Volkl S, Seitz K, Goossens C, Emons J, Ruebner M, et al.
BMC Immunol
. 2025 Mar;
26(1):21.
PMID: 40089714
Background: Peripheral blood mononuclear cells (PBMCs) are valuable biomarkers, providing crucial insights into the patients' immune system. Reliable biobanking of PBMCs is essential to minimize heterogeneity. In multicenter trials, blood...
2.
Behrens A, Dietl A, Adler W, Geppert C, Hartmann A, Knoll A, et al.
Arch Gynecol Obstet
. 2025 Mar;
PMID: 40088321
No abstract available.
3.
Behrens A, Huebner H, Haberle L, Stamminger M, Zint D, Heindl F, et al.
Breast Cancer
. 2025 Mar;
PMID: 40025401
No abstract available.
4.
Psilopatis I, Sipulina N, Stuebs F, Heindl F, Poeschke P, Bader S, et al.
Gynecol Obstet Invest
. 2025 Feb;
:1-15.
PMID: 39978322
Objective: To examine the potential of artificial intelligence (AI) in gynecologic oncology decision making. Design: Feasibility study. Setting: Fictive. Participants: Fictitious case vignettes of gynecologic carcinomas. Methods: Fictitious case vignettes...
5.
Hoppe R, Winter S, Lo W, Michailidou K, Bolla M, Keeman R, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):18.
PMID: 39971965
The role of germline genetics in adjuvant aromatase inhibitor (AI) treatment efficacy in ER-positive breast cancer is poorly understood. We employed a two-stage candidate gene approach to examine associations between...
6.
Heindl F, Schiel J, Hack C, Amann N, Jud S, Preuss C, et al.
Breast Cancer Res Treat
. 2025 Feb;
PMID: 39960605
Purpose: Unclear or suspicious breast findings are typically clarified by interventional breast biopsy. Lesions with uncertain malignant potential are grouped as B3 lesions in histopathology. The B3 group according to...
7.
Walter C, Hartkopf A, Hein A, Fasching P, Kolberg H, Hadji P, et al.
Breast
. 2025 Feb;
80:104412.
PMID: 39952220
Background: Patients with first-line metastatic breast cancer (MBC) comprise patients with de novo metastases (dnMBC) or recurrent disease after primary breast cancer (rMBC). This analysis aimed to explore the prognostic...
8.
Kehl S, Karademir Z, Weiss C, Titzmann A, Schneider M, Beckmann M, et al.
Geburtshilfe Frauenheilkd
. 2025 Feb;
85(2):210-218.
PMID: 39925951
Purpose: Misoprostol is used in low doses for the induction of labor. It is still not clear, however, which of the approved doses (25 µg or 50 µg) is more...
9.
Stuebs F, Dietl A, Schulmeyer C, Behrens A, Seibold A, Brueckner L, et al.
Anticancer Res
. 2025 Jan;
45(2):677-683.
PMID: 39890202
Background/aim: Cervical intraepithelial neoplasia (CIN) III/high-grade squamous lesions (HSIL) remains a significant challenge during pregnancy. Current data on the course of disease are contradictory, with cases of progression to cervical...
10.
Haberle L, Erber R, Gass P, Hein A, Niklos M, Volz B, et al.
Breast Cancer Res
. 2025 Jan;
27(1):13.
PMID: 39856787
Background: Pathological complete response (pCR) is an established surrogate marker for prognosis in patients with breast cancer (BC) after neoadjuvant chemotherapy. Individualized pCR prediction based on clinical information available at...